Trial · NCT01618695
Results by group40
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 40
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Core Phase: Percent Change in Seizure Frequency (For All Partial Seizures) Per 28 Days in the Randomization Phase Relative to Pre-randomization Phase (Baseline) | Placebo | -10.76 | Full Range -90.4 to 400.0 | percent change | |
| Core Phase: Percent Change in Seizure Frequency (For All Partial Seizures) Per 28 Days in the Randomization Phase Relative to Pre-randomization Phase (Baseline) | Perampanel 4 mg | -17.32 | Full Range -97.1 to 473.4 | percent change | |
| Core Phase: Percent Change in Seizure Frequency (For All Partial Seizures) Per 28 Days in the Randomization Phase Relative to Pre-randomization Phase (Baseline) | Perampanel 8 mg | -28.95 | Full Range -100.0 to 809.4 | percent change | |
| Core Phase: Percent Change in Seizure Frequency (For All Partial Seizures) Per 28 Days in the Randomization Phase Relative to Pre-randomization Phase (Baseline) | Perampanel 12 mg | -38.03 | Full Range -100.0 to 456.8 | percent change | |
| Core Phase: Responder Rate During the Maintenance Period of the Randomization Phase Relative to the Prerandomization Phase (Baseline)- Last Observation Carried Forward (LOCF) | Placebo | 19.4 | percentage of participants | ||
| Core Phase: Responder Rate During the Maintenance Period of the Randomization Phase Relative to the Prerandomization Phase (Baseline)- Last Observation Carried Forward (LOCF) | Perampanel 4 mg | 23.0 | percentage of participants | ||
| Core Phase: Responder Rate During the Maintenance Period of the Randomization Phase Relative to the Prerandomization Phase (Baseline)- Last Observation Carried Forward (LOCF) | Perampanel 8 mg | 36.0 | percentage of participants | ||
| Core Phase: Responder Rate During the Maintenance Period of the Randomization Phase Relative to the Prerandomization Phase (Baseline)- Last Observation Carried Forward (LOCF) | Perampanel 12 mg | 43.3 | percentage of participants | ||
Core Phase: Percent Change in Seizure Frequency Per 28 Days For Complex Partial Seizures Plus Secondary Generalized Seizures in the Randomization Phase Relative to the Prerandomization Phase (Baseline) | Placebo | -11.70 | Full Range -88.6 to 400.0 | percent change | |
Core Phase: Percent Change in Seizure Frequency Per 28 Days For Complex Partial Seizures Plus Secondary Generalized Seizures in the Randomization Phase Relative to the Prerandomization Phase (Baseline) | Perampanel 4 mg | -19.08 | Full Range -100.0 to 410.0 | percent change | |
Core Phase: Percent Change in Seizure Frequency Per 28 Days For Complex Partial Seizures Plus Secondary Generalized Seizures in the Randomization Phase Relative to the Prerandomization Phase (Baseline) | Perampanel 8 mg | -33.68 | Full Range -100.0 to 1103.4 | percent change | |
Core Phase: Percent Change in Seizure Frequency Per 28 Days For Complex Partial Seizures Plus Secondary Generalized Seizures in the Randomization Phase Relative to the Prerandomization Phase (Baseline) | Perampanel 12 mg | -41.80 | Full Range -100.0 to 456.8 | percent change | |
| Core Phase: Number of Participants With Clinical Global Impression of Change (CGIC) Scores | Placebo | Very much improved | 3 | Participants | |
| Core Phase: Number of Participants With Clinical Global Impression of Change (CGIC) Scores | Perampanel 4 mg | Very much improved | 5 | Participants | |
| Core Phase: Number of Participants With Clinical Global Impression of Change (CGIC) Scores | Perampanel 8 mg | Very much improved | 11 | Participants | |
| Core Phase: Number of Participants With Clinical Global Impression of Change (CGIC) Scores | Perampanel 12 mg | Very much improved | 9 | Participants | |
| Core Phase: Number of Participants With Clinical Global Impression of Change (CGIC) Scores | Placebo | Much improved | 31 | Participants | |
| Core Phase: Number of Participants With Clinical Global Impression of Change (CGIC) Scores | Perampanel 4 mg | Much improved | 39 | Participants | |
| Core Phase: Number of Participants With Clinical Global Impression of Change (CGIC) Scores | Perampanel 8 mg | Much improved | 41 | Participants | |
| Core Phase: Number of Participants With Clinical Global Impression of Change (CGIC) Scores | Perampanel 12 mg | Much improved | 54 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01618695/results